TARA-002 demonstrated compelling efficacy and was generally well-tolerated Enrollment in additional cohorts underway with initial results expected in 1H'25 NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinicalstage company developing transformative therapies for the treatment of cancer and rare diseases, today announced completion of the first cohort of the Phase 2 STARBORN-1 trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the trea ...

78% of patients dependent on parenteral support were choline deficient, with 63% of these patients demonstrating liver dysfunction, including steatosis, cholestasis, and hepatobiliary injury IV Choline Chloride could fill a significant unmet medical need for this population Company expects to dose first patient in pivotal PK trial for IV Choline Chloride in Q1 2025 NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinicalstage company developing transformative therap ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Delaware 20-4580525 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share TARA The Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITIO ...

Exhibit 99.1 Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update ● On track to report preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in Q4 2024 ● Expect to dose first patient in pivotal trial for IV Choline Chloride in Q1 2025 ● Current cash resources are approximately $90 million, including net proceeds from April 2024 private placement, expected to fund operations into 2026 NEW YORK, August 6, 2024 – Protara Thera ...

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grant of inducement non-qualified stock options to purchase an aggregate of 118,400 shares of common stock to Lisa Schlesinger, Protara's newly appointed Vice President, Head of New Product Development and Market Access. About Protara Therapeutics, Inc. Justine O'Malley Protara Therapeutics Justi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock, $0.001 par value per | TARA | The Nasdaq Capital Market | | share | ...

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update NEW YORK, May 2, 2024 – Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended March 31, 2024 and provided a business update. "We have made significant progress thus far in 2024, and with cash resources expected to fund operations into 2026, we are well pos ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...

Exhibit 99.1 Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update NEW YORK, March 13, 2023 – Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the full year and fourth quarter ended December 31, 2023 and provided a business update. "We expect 2024 to be a milestone-rich year for Protara and believe we are well po ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36694 Protara Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incor ...